Current Hypertension Reports

, Volume 1, Issue 2, pp 187–194 | Cite as

New insights into the renin-angiotensin system and hypertensive renal disease

  • Agnes B. Fogo


The role of the renin-angiotensin system in hypertension and end organ damage has long been recognized. Recent advances in genetic models and newly available pharmacologic tools have allowed dissection of the mechanisms of actions of the renin-angiotensin system in hypertensive kidney disease. The newly cloned AT2 receptor is now recognized to oppose many of the AT1 receptor’s actions. The renin-angiotensin system is now recognized to be linked to induction of plasminogen activator inhibitor-1 (PAI-1), possibly via the AT4 receptor, thus promoting both thrombosis and fibrosis. Interactions of the reninangiotensin system with aldosterone and bradykinin may have impact on both blood pressure and tissue injury. The effects of angiotensin 1 converting enzyme inhibitors versus those of the newly available AT1 receptor antagonists on blood pressure and organ damage are undergoing evaluation in clinical trials. Finally, polymorphisms of genes relevant to the renin-angiotensin system appear to affect response to treatment, although this effect varies in different populations.


Angiotensin Converting Enzyme Losartan Angiotensinogen Angiotensin Converting Enzyme Genotype Reninangiotensin System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kasiske BL, Kalil RS, Ma JZ, et al.: Effect of antihypertensive therapy on the kidney in patients with diabetes: a metaregression analysis. Ann Intern Med 1993, 118:129–138.PubMedGoogle Scholar
  2. 2.
    Esther CR, Marino EM, Howard TE, et al.: The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 1997, 99:2375–2385. Local, rather than plasma ACE is shown to be the critical mediator of blood pressure.PubMedGoogle Scholar
  3. 3.
    Kim HS, Krege JH, Kluckman KD, et al.: Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A 1995, 92:2735–2739.PubMedCrossRefGoogle Scholar
  4. 4.
    Niimura F, Labosky PA, Kakuchi J, et al.: Gene targeting in mice reveals a requirement for angiotensin in the development and maintenance of kidney morphology and growth factor regulation. J Clin Invest 1995, 96:2947–2954.PubMedGoogle Scholar
  5. 5.
    Hilgers KF, Reddi V, Krege JH, et al.: Aberrant renal vascular morphology and renin expression in mutant mice lacking angiotensin-converting enzyme. Hypertension 1997, 29:216–221.PubMedGoogle Scholar
  6. 6.
    Esther CR Jr, Howard TE, Marino EM, et al.: Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996, 74:953–965.PubMedGoogle Scholar
  7. 7.
    Chen X, Li W, Yoshida H, Tsuchida S, et al.: Targeting deletion of angiotensin type 1B receptor gene in the mouse. Am J Physiol 1997, 272:F299-F304.PubMedGoogle Scholar
  8. 8.
    Tsuchida S, Matsusaka T, Chen X, et al.: Murine double nullizygotes of the angiotensin type 1A and type 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. J Clin Invest 1998, 101:755–760.PubMedGoogle Scholar
  9. 9.
    Yamada T, Horiuchi M, Dzau VJ: Angiotensin type 2 receptor mediates programmed cell death. Proc Natl Acad Sci U S A 1996, 93:156–160.PubMedCrossRefGoogle Scholar
  10. 10.
    Ichiki, T, Labosky PA, Shiota C, et al.: Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. Nature 1995, 377:748–750.PubMedCrossRefGoogle Scholar
  11. 11.
    Ma J, Nishimura H, Fogo A, et al.: Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998, 53:937–944. The antifibrotic role of the AT2 receptor is shown.PubMedCrossRefGoogle Scholar
  12. 12.
    Ohkubo N, Matsubara H, Nozawa Y, et al.: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997, 96:3954–3962.PubMedGoogle Scholar
  13. 13.
    Nakajima M, Hutchinson HG, Fujinaga M, et al.: The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A 1995, 92:10663–10667.PubMedCrossRefGoogle Scholar
  14. 14.
    Yerkes E, Nishimura H, Miyazaki Y, et al.: Role of angiotensin in the congential anomalies of the kidney and urinary tract in the mouse and the human. Kidney Int 1998, 54(Suppl 67):S75-S77. Novel action of angiotensin, via the AT2 receptor, on the development of the urinary tract, with implications for congential abnormalities and antihypertensive treatment in premature infants in whom the kidney has not yet fully developed.CrossRefGoogle Scholar
  15. 15.
    Miyazaki Y, Tsuchida S, Nishimura H, et al.: Angiotensin induces the urinary peristaltic machinery during the perinatal period. J Clin Invest 1998, 102:1489–1497.PubMedGoogle Scholar
  16. 16.
    Handa RK, Krebs LT, Harding JW, Handa SE: Angiotensin IV AT4-receptor system in the rat kidney. Am J Physiol 1998, 274:F290–299.PubMedGoogle Scholar
  17. 17.
    Coleman JK, Krebs LT, Hamilton TA, et al.: Autoradiographic identification of kidney angiotensin IV binding sites and angiotensin IV-induced renal cortical blood flow changes in rats. Peptides 1998, 19:269–277.PubMedCrossRefGoogle Scholar
  18. 18.
    Zhang JH, Stobb JW, Hanesworth JM, et al.: Characterization and purification of the bovine adrenal angiotensin IV receptor (AT4) using [125I]Benzoylphenylalanine-angiotensin IV as a specific photolabel. J Pharmacol Exp Ther 1998, 287:416–424.PubMedGoogle Scholar
  19. 19.
    Yang Q, Hanesworth JM, Harding JW, Slinker BK: The AT4 receptor agonist [Nle1]-angiotensin IV reduces mechanically induced immediate-early gene expression in the isolated rabbit heart. Regul Pept 1997, 71:175–183.PubMedCrossRefGoogle Scholar
  20. 20.
    Brown NJ, Vaughan DE: The renin-angiotensin and fibrinolytic systems: co-conspirators in the pathogenesis of ischemic cardiovascular disease. Trends Cardiovasc Med 1996, 6:239–243.CrossRefGoogle Scholar
  21. 21.
    Langheinrich M, Lee MA, Böhm M, et al.: The hypertensive Ren-2 transgenic rat TGR (mREN2)27 in hypertension research. Am J Hyperten 1996, 9:506–512.CrossRefGoogle Scholar
  22. 22.
    Bohlender J, Fukamizu A, Lippoldt A, et al.: High human renin hypertension in transgenic rats. Hypertension 1997, 29:428–434.PubMedGoogle Scholar
  23. 23.
    Kai T, Kino H, Sugimura K, et al.: Significant role of the increase in renin-angiotensin system in cardiac hypertrophy and renal glomerular sclerosis in double transgenic tsukuba hypertensive mice carrying both human renin and angiotensinogen genes. Clin Exp Hypertens 1998, 20:439–449.PubMedCrossRefGoogle Scholar
  24. 24.
    Nguyen G, Delarue F, Berrou J, et al.: Specific receptor binding of renin on human mesangial cells in culture increases plasminogen activator inhibitor-1 antigen. Kidney Int 1996, 50:1897–1903.PubMedCrossRefGoogle Scholar
  25. 25.
    Brown NJ, Nadeau JH, Vaughan DE: Selective stimulation of tissue-type plasminogen activator (t-PA) in vivo by infusion of bradykinin. Thromb Haemost 1997, 77:522–525.PubMedGoogle Scholar
  26. 26.
    Kon V, Fogo A, Ichikawa I: Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition. Kidney Int 1993, 44:545–550.PubMedGoogle Scholar
  27. 27.
    Endlich K, Steinhausen M: Role of kinins and angiotensin II in the vasodilating action of angiotensin converting enzyme inhibition in rat renal vessels. J Hypertension 1997, 15:633–641.CrossRefGoogle Scholar
  28. 28.
    Naitoh M, Suzuki H, Arakawa K, et al.: Role of kinin and renal ANG II blockade in acute effects of ACE inhibitors in lowrenin hypertension. Am J Physiol 1997, 272:H679-H687.PubMedGoogle Scholar
  29. 29.
    Gainer JV, Morrow JD, King DJ, Brown NJ: Effect of bradykinin receptor blockade on the response to angiotensin-converting enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998, 339:1285–1292. The contribution of bradykinin to the hypotensive effect of ACEI is demonstrated in humans.PubMedCrossRefGoogle Scholar
  30. 30.
    Kagami S, Kuhara T, Okada K, et al.: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997, 51:664–671.PubMedCrossRefGoogle Scholar
  31. 31.
    Brown NJ, Agirbasli MA, Williams GH, et al.: Effect of activation and inhibition of the renin-angiotensin system on PAI-1 in humans. Hypertension 1998, 32:965–971. Modulation of PAI-1 by the RAS in humans is shown.PubMedGoogle Scholar
  32. 32.
    Kimura H, Gejyo F, Suzuki Y, et al.: Effects of polymorphisms in angiotensin converting enzyme and plasminogen activator-1 genes on the development of diabetic nephropathy and macroangiopathy. Kidney Int 1998, 54:1659–1669.PubMedCrossRefGoogle Scholar
  33. 33.
    Chabielska E, Pawlak R, Golatowski J, Buczko W: The antithrombotic effect of captopril and losartan on experimental arterial thrombosis in rats. J Physiol Pharmacol 1998, 49:251–260.PubMedGoogle Scholar
  34. 34.
    Oikawa T, Freeman M, Lo W, et al.: Modulation of plasminogen activator inhibitor-1 in vivo: a new mechanism for the anti-fibrotic effect of renin-angiotensin inhibition. Kidney Int 1997, 51:164–172.PubMedCrossRefGoogle Scholar
  35. 35.
    Hamdan AD, Quist WC, Gagne JB, Feener EP: Angiotensinconverting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of ballooninjured rat aorta. Circulation 1996, 93:1073–1078.PubMedGoogle Scholar
  36. 36.
    Vaughan DE, Rouleau JL, Ridker PM, et al.: Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 1997, 96:442–447.PubMedGoogle Scholar
  37. 37.
    Greene EL, Kren S, Hostetter TH: Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 1996, 98:1063–1068.PubMedGoogle Scholar
  38. 38.
    Ibrahim HN, Rosenberg ME, Hostetter TH: Role of the reninangiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 1997, 17:431–440. The evidence linking aldosterone to end organ fibrosis is reviewed.PubMedGoogle Scholar
  39. 39.
    Rocha R, Chander PN, Khanna K, et al.: Mineralocorticoid blockade reduces vascular injury in stroke-prone rats. Hypertension 1998, 31:451–458.PubMedGoogle Scholar
  40. 40.
    Benetos A, Lacooey O, Safar ME: Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997, 17:1152–1156.PubMedGoogle Scholar
  41. 41.
    Brown NJ, Chen Y-Q, Vaughan DE: Synergistic effects of aldo and angiotensin II on PAI-1 expression [abstract]. Circulation 1998, 98:I2729.Google Scholar
  42. 42.
    Okubo S, Niimura F, Nishimura H, et al.: Angiotensin-independent mechanism for aldosterone synthesis during chronic extracellular fluid voulume depletion. J Clin Invest 1997, 99:855–860. Induction of aldosterone in the absence of angiotensin is shown to be dependent on potassium.PubMedGoogle Scholar
  43. 43.
    Weir MR, Dworkin LD: Antihypertensive drugs, dietary salt, and renal protection: How low should you go and with which therapy? Am J Kidney Dis 1998, 32:1–22.PubMedGoogle Scholar
  44. 44.
    Giatras I, Lau J, Levey AS, for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group: Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med 1997, 127:337–345. This review of randomzied trials confirms efficacy of ACE on progression of renal diseases, with a lower mean arterial pressure achieved with this drug versus other antihypertensives.PubMedGoogle Scholar
  45. 45.
    Brown NJ, Vaughan DE: Angiotensin-converting enzyme inhibitors. Circulation 1998, 97:1411–1420. Excellent review of pharmacology and mechanisms of actions of ACEI, and ongoing cardiovascular trials with angiotensin inhibitors.PubMedGoogle Scholar
  46. 46.
    Nielsen S, Dollerup J, Nielsen B, et al.: Losartan reduces albuminuria in patients with essential hypertension: an enalapril controlled 3 months study. Nephrol Dial Transplant 1997, 12(Suppl 2):19–23.PubMedGoogle Scholar
  47. 47.
    Maschio G, Alberti D, Janin G, et al.: Effect of the angiotensinconverting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996, 334:939–945.PubMedCrossRefGoogle Scholar
  48. 48.
    Pitt B, Segal R, Martinez FA, et al.: Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997, 349:747–752. This large, randomized trial of ACEI-naive patients with congestive heart failure demonstrated tolerability of the AT1 receptor antagonist, without increased serum creatinine. Surprisingly, even lower mortality, due to decreased sudden death, was observed with losartan versus ACEI.PubMedCrossRefGoogle Scholar
  49. 49.
    Hein L, Stevens ME, Barsh GS, et al.: Overexpression of angiotensin AT1 receptor transgene in the mouse myocardium produces a lethal phenotype associated with myocyte hyperplasia and heart block. Proc Natl Acad Sci U S A 1997, 94:6391–6396. The impact of the AT1 receptor on heart rhythm is demonstrated.PubMedCrossRefGoogle Scholar
  50. 50.
    Mackenzie HS, Ots M, Ziai F, et al.: Angiotensin receptor antagonists in experimental models of chronic renal failure. Kidney Int 1997, 63:S140-S143.Google Scholar
  51. 51.
    Ots M, Mackenzie HS, Troy JL, et al.: Effects of combination therapy with enalapril and losartan on the rate of progression of renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol 1998, 9:224–230.PubMedGoogle Scholar
  52. 52.
    Richer C, Bruneval P, Menard J, Giudicelli JF: Additive effects of enalapril and losartan in (mREN-2)27 transgenic rats. Hypertension 1998, 31:692–698.PubMedGoogle Scholar
  53. 53.
    Mitchell HC, Smith RD, Cutler RE, et al.: Racial differences in the renal response to blood pressure lowering during chronic angiotensin-converting enzyme inhibition: a prospective double-blind randomized comparison of fosinopril and lisinopril in older hypertensive patients with chronic renal insufficiency. Am J Kidney Dis 1997, 29:897–906.PubMedGoogle Scholar
  54. 54.
    Fogo A, Breyer JA, Smith MC, et al.: Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) trial. Kidney Int 1997, 51:244–252. This renal biopsy study confirms that African-American patients with a clinical diagnosis of hypertensive nephrosclerosis have morphologic findings consistent with that diagnosis, with marked global glomerulosclerosis.PubMedCrossRefGoogle Scholar
  55. 55.
    Hunley TE, Julian BA, Phillips JA, et al.: Angiotensin converting enzyme gene polymorphism: potential silencer motif and impact on progression in IgA nephropathy. Kidney Int 1996, 49:571–577.PubMedCrossRefGoogle Scholar
  56. 56.
    Yoshida H, Mitarai T, Kawamura T, et al.: Role of the deletion polymorphism of the angiotensin converting enzyme gene in the progression and therapeutic responsiveness of IgA nephropathy. J Clin Invest 1995, 96:2162–2169.PubMedCrossRefGoogle Scholar
  57. 57.
    Jacobsen P, Rossing K, Rossing P, et al.: Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney Int 1998, 53:1002–1006. Efficacy of ACEI on proteinuria in these hypertensive insulin-dependent with diabetic nephropathy was greatest in those with II ACE genotype.PubMedCrossRefGoogle Scholar
  58. 58.
    Penno G, Chaturvedi N, Talmud PJ, et al.: Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM. Diabetes 1998, 47:1507–1511. A large controlled trial that demonstrates enhanced response to ACEI in patients with II ACE genotype.PubMedCrossRefGoogle Scholar
  59. 59.
    Haas M, Yilmaz N, Schmidt A, et al.: Angiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. Kidney Blood Press Res 1998, 21:66–69.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 1999

Authors and Affiliations

  • Agnes B. Fogo
    • 1
  1. 1.MCN C3310, Department of PathologyVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations